1 Racial and Ethnic Disparities in the Utilization and Outcomes with WATCHMAN FLX: A

2 SURPASS analysis of the NCDR LAAO Registry

- 3 Authors: Oluseun O Alli, MD,^a Jalaj Garg, MD,^b Brian C. Boursiquot, MD, MS^c, Samir R
- 4 Kapadia, MD,^d Robert W Yeh, MD, MSc,^e Matthew J Price, MD,^f Jonathan P Piccini, MD,
- 5 MHS,^g Devi G Nair, MD,^h Jonathan C Hsu, MD,ⁱ Douglas N Gibson, MD,^j TDominic Alloco
- 6 MD, ^k Thomas Christen, MD PhD, ^k Brad Sutton, MD, ^k and James V Freeman, MD, MPH, MS¹
- ⁷ ^aDivision of Cardiology, Novant Health Heart and Vascular Institute, Charlotte, NC; ^bDivision of
- 8 Cardiology, Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, MN;
- ⁹ ^cDepartment of Medicine Columbia University Irving Medical Center New York NY;
- ¹⁰ ^dDepartment of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland
- 11 Clinic, Cleveland, Ohio, USA; ^eRichard A. and Susan F. Smith Center for Outcomes Research in
- 12 Cardiology, Beth Israel Deaconess Medical Center, Boston, MA; ^fDivision of Cardiovascular
- 13 Diseases, Scripps Clinic, La Jolla, CA; ^gDivision of Cardiology, Duke University Medical
- 14 Center, Durham, North Carolina, USA; ^hDepartment of Cardiac Electrophysiology, St. Bernard's
- 15 Heart and Vascular Center, Jonesboro, Arkansas, USA; ⁱCardiac Electrophysiology Section,
- 16 Division of Cardiology, Department of Medicine, University of California, San Diego,
- 17 California, USA; ^jDivision of Cardiovascular Diseases, Scripps Clinic, La Jolla, California,
- 18 USA; ^kBoston Scientific Corp, Marlborough, Massachusetts, USA; ^lSection of Cardiovascular
- 19 Medicine, Yale University School of Medicine, New Haven, Connecticut and Center for
- 20 Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA
- 21 Short Title: Racial Disparities in Use and Outcomes after LAAO

22 Address for Correspondence:

- 23 Oluseun O Alli
- 24 Division of Cardiology
- 25 Novant Heart and Vascular Institute
- 26 Charlotte NC 28204
- 27 Email: <u>seunnalli@gmail.com</u>
- 28

29 Total Word Count: 6156 (including Title Page, Abstract, Text, References, Tables and Figures

- 30 Legends)
- 31
- 32

1 Abstract (N=250 words; currently N=267)

2	Background: Left atrial appendage occlusion (LAAO) is increasingly used as an alternative to
3	oral anticoagulation for stroke prevention in select patients with atrial fibrillation. Data on
4	outcomes in racial and ethnic minority individuals are limited. This analysis assessed differences
5	in the utilization and outcomes of LAAO by race and ethnicity in a large national registry.
6	Methods: This analysis acquired data on WATCHMAN FLX patients from the National
7	Cardiovascular Data Registry (NCDR) LAAO Registry through September 2022. All patients
8	with an attempted WATCHMAN FLX implantation and known race and ethnicity were
9	included. Baseline characteristics and 1 year event rates were compared.
10	Results: A total of 97,185 patients were analyzed; 87,339 were White (90%), 3,750 Black
11	(Black/African American 3.9%), and 2,866 Hispanic ([Hispanic/Latinx] 2.9%). Black and
12	Hispanic patients were younger with a higher incidence of prior stroke and significant bleeding
13	compared to White patients. Black and Hispanic patients were treated with LAAO in smaller
14	numbers relative to their proportion of the US population. Rates of procedural success were
15	similar between groups. Though direct oral anticoagulants were prescribed in most patients
16	across the groups, dual and single antiplatelet therapy were prescribed more often in Black
17	patients. Black patients had significantly higher rates of 1-year death and bleeding compared to
18	White and Hispanic patients.
19	Conclusions: Patients from racial and ethnic minority groups comprise a disproportionately
20	small fraction of all patients who undergo LAAO. Black and Hispanic patients were younger but
21	had significantly higher comorbidities compared to White patients. Procedural success was
22	similar amongst the groups but Black patients experienced higher rates of death and bleeding at 1
23	year.

1	Keywords (up to 6)
2	Racial disparity, left atrial appendage occlusion, atrial fibrillation, bleeding, stroke
3	
4	Abbreviations list (up to 10)
5	ACC = American College of Cardiology
6	LAAO = left atrial appendage occlusion
7	NCDR = National Cardiovascular Data Registry
8	AF = atrial fibrillation
9	OAC = oral anticoagulation
10	DAPT = dual antiplatelet therapy
11	DOAC = direct oral anticoagulant
12	

13 Introduction

Transcatheter left atrial appendage occlusion (LAAO) is an increasingly utilized alternative 14 15 therapy to long-term anticoagulation for stroke prevention in selected patients with nonvalvular 16 atrial fibrillation (AF). Stroke is the most devastating complication of AF, and the use of oral anticoagulation or LAAO has been shown to be effective at reducing stroke risk.^{1,2} Despite the 17 18 effectiveness of anticoagulation, racial and ethnic minority patients, and particularly Black 19 patients diagnosed with AF, are less likely to be discharged on oral anticoagulants, while also having a higher risk of stroke compared to White patients.^{3,4} Similarly, it has been shown that 20 21 there are significant racial and ethnic disparities in structural heart disease interventions, including LAAO⁵, with one study showing that racial and ethnic minority patients comprised less 22

than 4% of those treated with these advanced interventions between 2011 and 2016.⁵ Racial and
ethnic minority individuals have also been consistently shown to be undertreated in terms of
other cardiovascular procedures like transcatheter aortic valve replacement (TAVR), mitral valve
replacement, and implantation of implantable cardioverter-defibrillators.^{6–9}

5 In published clinical trials and real-world experience with transcatheter LAAO, non-6 Hispanic White patients have represented over 90% of cases; it is not clear that the efficacy in 7 the overall population is generalizable to all racial and ethnic groups. Studies of racial and ethnic 8 disparities in transcatheter LAAO outcomes have shown higher rates of in-hospital 9 complications among non-Hispanic Black and Hispanic patients compared to non-Hispanic 10 White patients.¹⁰ However, there is a paucity of data comparing post-discharge outcomes across 11 racial and ethnic groups.

12 The SURPASS registry is an analysis of patients who underwent LAAO with the 13 WATCHMAN FLX device as part of the American College of Cardiology (ACC) Foundation's 14 National Cardiovascular Data Registry (NCDR) LAAO Registry. The aim of this current 15 analysis is to examine the utilization of and outcomes after WATCHMAN FLX LAAO across 16 racial and ethnic groups in a large national registry.

17 Methods

18 Data Source

19 This analysis included data on patients implanted with the WATCHMAN FLX device 20 (Boston Scientific, Marlborough, MA, USA) and included in the NCDR LAAO Registry. This 21 registry was initiated in December 2015 after FDA approval of the first WATCHMAN device.¹¹ 22 The NCDR LAAO Registry serves as the formal post-market surveillance vehicle required by

the FDA for the WATCHMAN device, and it is the only registry approved by CMS to satisfy the coverage decision data submission requirement.¹² As of April 2016, U.S. hospitals were required to submit data for all WATCHMAN procedures into the LAAO Registry to qualify for Medicare reimbursement. Hospitals are encouraged to submit data on all device recipients regardless of insurance status.

The LAAO Registry data collection methods have been detailed previously.¹¹ In brief, the 6 7 LAAO Registry collects approximately 220 data elements from the implant hospitalization, 60 8 for each follow-up visit, and 15 data elements to support the adjudication of adverse events. Data 9 are collected at discharge, and follow-up visits over the first year occur at 45 days (± 14 days), 10 180 days (-30 days/+60 days), and 365 days (±60 days). The NCDR Data Quality Reporting 11 process is designed to ensure that submissions are complete, valid, and accurate; it involves an 12 annual audit of about 5% of sites that are randomly selected during which submitted data are compared with source documentation and billing data.¹³ The LAAO Registry developed and 13 14 validated a novel process to adjudicate adverse clinical events over follow-up. A computer-based 15 algorithm uses discrete combinations of registry data elements based on standard event definitions to adjudicate adverse events.¹⁴ Cases are manually adjudicated when registry data 16 17 elements are incomplete or conflicting. Adjudicated adverse events in the registry include 18 ischemic stroke, hemorrhagic stroke, undetermined stroke, transient ischemic attack, intracranial 19 hemorrhage, systemic arterial embolism (other than stroke), major bleeding, and major vascular 20 complications.

21 Study Population

This analysis utilized patient data collected between August 5, 2020 to September 30, 2022. All
patients with attempted WATCHMAN FLX implantation were included. The data collection

1 form of the NCDR LAAO registry has a racial category question and a Hispanic or Latinx 2 ethnicity question. Analysis cohorts were based on the selections within these two questions. 3 Race and/or Hispanic or Latinx ethnicity was determined by the patient/family and site-reported. 4 Groups were then defined as White [non-Hispanic White], Black [non-Hispanic Black/African 5 American], Asian [non-Hispanic Asian], Native American/Pacific Islander [non-Hispanic 6 American Indian/Alaska Native/Native Hawaiian/Pacific Islander] and Hispanic [Hispanic or 7 Latinx]. Additional groups included: multiple selections (if multiple categories were selected), 8 other (one of the two questions was not answered), and no race or ethnicity reported (neither 9 question was answered). Patient and procedure characteristics and outcomes in patients with 10 multiple selections, other or no selection can be found in **Supplemental Tables 1-4**.

11 Study Endpoints

All-cause death, stroke [ischemic and/or hemorrhagic], and major bleeding [any bleeding
requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or
requiring blood transfusion that was not hemorrhagic stroke ¹¹] were evaluated at 45 days and 1
year. Additional endpoints evaluated at 45 days include major vascular complications,
pericardial effusion, device embolization, device migration, and peridevice leak. *Statistical Analysis*

Data were summarized using descriptive statistics for continuous variables and frequency tables or proportions for discrete variables. P-values were from the Fisher exact or chi square test, as appropriate. Clinical event rates at 45 days and 1 year were estimated using the Kaplan-Meier method with p-values from the log-rank test. Adjustment or differences in baseline characteristics was performed in the three largest groups. Cox proportional hazards regression was performed for the comparisons between White and Black and White vs Hispanic patients. Candidate variables are included in the Supplement. The following variables, based on clinical
relevance and with a p<0.02 in univariate analyses were included: age, gender, components of
the CHA₂DS₂-VASc and/or HAS-BLED scores, type of AF, fall risk, chronic lung disease, sleep
apnea, cardiomyopathy, coronary artery disease, prior ablation, and left ventricular ejection
fraction. Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, North
Carolina).

7 **Results**

8 A total of 97,185 patients were implanted with WATCHMAN FLX between August 5, 2020 and 9 September 30, 2022 at 772 sites in the United States. Most patients were White (90%, n=87339); 10 Black patients comprised 3.9% (n=3750), Hispanic 2.9% (n=2866), Asian 1.1% (n=1082), and 11 American Indian/Pacific Islander 0.3% (n=274) of the patient population. Data from other groups 12 can be found in the **Supplement (Supplemental Tables 1-3, 5 and 7)** including 297 patients 13 with multiple races/ethnicities selected (0.3%), 1255 (1.3%) who did not have data for both race 14 and ethnicity and 322 who did not have data for either race or ethnicity (0.3%). 15 **Baseline** Characteristics 16 Overall, there were significant differences in baseline characteristics between racial and ethnic

17 groups. Black and Native American/Pacific Islander patients were several years younger than

18 other groups and had the largest ratio of women to men (**Table 1**). The CHA₂DS₂-VASc score

19 was highest in Black, Hispanic and Native American/Pacific Islander patients; and HAS-BLED

20 was highest in Black patients. Prior stroke was highest in Black and Asian patients and prior

21 bleeding highest in Black patients.

1 Procedural Characteristics

Indications for LAAO were consistent across the groups and mainly related to risk of bleeding
and/or stroke (Table 2). Device size tended to be larger in Black and Asian patients. Same day
discharge rates ranged from 21.5% to 38.2%. The rates of successful implantation and complete
seal at post-procedure were high in all groups. Direct oral anticoagulation (DOAC) alone and
DOAC + aspirin were prescribed in the majority of patients across all groups. Dual antiplatelet
therapy (DAPT) and single antiplatelet therapy (SAPT) were prescribed more often in Black
patients than other groups (Table 3).

9 Outcomes at 45 days

10 Outcomes at 45 days, unadjusted for differences in baseline characteristics, are shown in **Figure** 11 1 and **Supplemental Table 4**. Death occurred in 0.81% of patients overall at 45 days and was 12 not statistically different across racial and ethnic groups ranging from 0.41% in Native 13 American/Pacific Islanders to 1.10% in Black patients. Stroke occurred in 0.29% of patients 14 overall and was highest in Asian patients (0.80%) at 45 days. The rate of major bleeding in all 15 patients combined was 3.11% at 45 days. There were significant statistical differences overall, 16 the highest rates were found in Black patients (4.92%) and Native American/Pacific Islanders 17 (4.89%). Peridevice leak at 45 days was similar across groups.

Cox proportional hazard regression analysis to adjust for differences in baseline characteristics, was performed in the three largest racial and ethnic groups using White patients as the reference group (**Table 4**, **Figure 2**). After adjustment, the risk of bleeding was significantly higher at 45 days in Black compared to White patients (HR 1.30, 95% confidence interval 1.10, 1.54). Death and stroke were similar between Black and White patients after adjustment. No differences in death, stroke or bleeding were found in White vs Hispanic patients

1 at 45 days after adjustment.

2 Outcomes at 1 year

3 Outcomes at 1 year are show in Figure 1 and 2, Supplemental Table 6. At 1 year, the rate of 4 unadjusted mortality was 8.15% and was significantly different across the racial and ethnic 5 groups. Native American/Pacific Islanders (15.79%) and Black (11.24%) had the highest rates of 6 death at 1 year. Major bleeding in the overall patient cohort was 6.37% at 1 year and varied 7 significantly among racial and ethnic groups. Major bleeding was highest in Native 8 American/Pacific Islanders (10.32%) and Black (10.91%) patients compared to the other groups 9 (Figure 1 and 2, Supplemental Table 6). Stroke overall at 1 year was 1.48% and, though not 10 statistically significantly different, ranged from 1.37% in Asian patients to 2.28% in Black 11 patients.

After adjustment, the risk of death and bleeding was significantly higher in Black compared to White patients at 1 year (death: 1.26 [1.06, 1.50]; bleeding: HR 1.36 [1.15, 1.60]). Hispanic and White patients had similar risk of death and bleeding at 1 year. The risk of stroke was similar between groups in each comparison (White vs Black or White vs Hispanic) after adjustment at 1 year.

17 **Discussion**

This study is the largest analysis of racial and ethnic differences in utilization and outcomes of LAAO procedures in the US to date including almost 100,000 patients. We demonstrated the following key findings: 1) significant racial and ethnic disparities exist, less than 4% Black and less than 3% and Hispanic patients comprise patients receiving LAAO ; 2) Black patients undergoing LAAO are significantly younger but with more comorbidities than White patients undergoing the procedure; and 3) the risk of death at 1 year and major bleeding at 45 days and 1
 year was higher for Black patients compared to White patients.

3 Disparities in Access to LAAO

4 The racial and ethnic representation among WATCHMAN FLX recipients in this study 5 mirrors the low enrollment of racial and ethnic minority patients in clinical trials involving these 6 devices. The PROTECT-AF and PREVAIL trials that that led to US FDA approval for the 7 WATCHMAN device had very few minority patients with 1.3% and 2.2% Black enrollment, respectively, as compared to >90% White enrollment in both trials.^{15,16} Similar disparities in real 8 world LAAO utilization have been previously described in other observational studies.^{10,17–19} An 9 10 important consideration that affects access of racial and ethnic minority patients to LAAO 11 procedures is the location of hospitals/centers that perform the procedures. An analysis of 12 Medicare fee-for-service claims (2016 to 2019) by Reddy and colleagues revealed that between 2016 and 2019, 97.4% of new LAAO programs opened in the US were in metropolitan areas.⁷ 13 14 The authors found that LAAO centers, as compared to non-LAAO centers, provided care to patients with higher median household incomes. After adjustment for socioeconomic markers, 15 age, and clinical comorbidities, LAAO procedures were less likely to be performed in zip codes 16 with higher proportions of Black and Hispanic patients.⁷ Another important consideration that 17 18 affects the demographic composition of those who undergo LAAO procedures is that White patients have a higher risk of AF than other racial and ethnic groups.⁴ However, this only 19 20 explains some of the underrepresentation of racial and ethnic minority groups among LAAO 21 patients. In one analysis using the National Inpatient Sample (NIS, a 20% random, stratified 22 sample of hospital discharges in the US), there were racial and ethnic differences in adult 23 admissions related to a diagnosis of AF where more than 80% were White, 9.3% were Black,

5.7% were Hispanic, 2% were Asian American and Pacific Islander, and 2.4% were of other
races and ethnicities.¹⁸ However, the proportions of racial and ethnic minority patients
undergoing LAAO procedures was still lower than their proportions among AF admissions.
Examining the racial and ethnic make-up of the patients who underwent LAAO in this study,
Black patients made up only 4.2% and Hispanic patients 5.0% of LAAO patients.¹⁸ Similar
underrepresentation was seen in other NIS analyses.^{10,17,19}

7 Disparities in LAAO Outcomes

8 Prior analyses have focused on short-term outcomes and found differences in major adverse 9 events between White patients and racial and ethnic minority patients regarding intra-procedural 10 or immediate postprocedural complications even after adjusting for differences in baseline 11 characteristics.^{10,17–19} SURPASS patients were followed up to a year and the rates of major 12 adverse events at 45 days and 1 year were similar in White and Hispanic patients. However, the 13 risk of death at 1 year and major bleeding at 45 days and 1 year was higher for Black patients 14 compared to White patients even after adjustment for differences in baseline comorbidities.

15 The differences in outcomes in this study may be related to differences in medical 16 comorbidities. Black and Hispanic patients had higher CHA₂DS₂-VASc and HAS-BLED scores. 17 Additionally, Black patients had the highest incidence of prior bleeding and more than twice the 18 incidence of abnormal renal function compared to White patients. This increase in bleeding in 19 Black patients may be driven by worse renal function in this patient population. These data echo 20 other studies focusing on the impact of race and ethnicity after LAAO. Compared with White patients, more Black patients, Hispanic patients, and patients of Asian, Asian American, or 21 22 Pacific Islander ancestry had diabetes mellitus, chronic kidney disease, previous stroke, and 23 deficiency anemias.¹⁸

Black patients were more commonly discharged on anticoagulation plus aspirin or DAPT instead of anticoagulation alone, which has been previously been reported to be associated with higher rates of bleeding after LAAO.²⁰ The increased use of antiplatelet agents may be indicated in this population with a higher burden of cardiovascular and renal comorbidities but could impact the difference in outcomes that were found between White and Black patients. Residual confounding due to unreported patient characteristics, disparities in access to LAAO, and postprocedural care may also account for some of the differences in bleeding and mortality observed.

8 Future Directions

9 Disparities leading to inadequate access to structural heart interventions remains a challenge in 10 other areas as well, as similar single digit representation of African American and Hispanic patients were found in the TAVR population.^{5,9,21} An analysis of the Transcatheter Valve 11 12 Therapy Registry of patients undergoing TAVR in the US revealed only 3.8% of patients were African American compared to 91.3% White patients.⁹ Similar findings have been found for 13 14 other cardiovascular procedures including mitral valve replacement, and implantation of implantable cardioverter-defibrillators.^{6,8,9} There is a pressing need to increase enrollment of 15 16 minority patients into clinical trials either by way of mandated enrollment targets, broadening the 17 clinical trial sites to include hospitals serving predominantly racial and ethnic minoritized patients and including investigators who also serve this patient population in clinical trials. 18 19 Strategies to improve access should also include efforts to train providers and help develop 20 infrastructure at centers that provide care to mainly minority patients. Interestingly, hospitals in 21 urban centers with a large minority population still have low treatment rates of minority patients⁷, suggesting that low enrollment rates are not just a location issue. Efforts must be made 22 23 to address barriers to care even in hospitals serving predominantly minority communities. Even

if trial enrollment of minority populations improves, the absolute numbers of minority patients
 may remain relatively modest, particularly for device trials which tend to be smaller, precluding
 detailed assessments of differences in outcomes. Real-world registry data serves as a
 complement to smaller trials for the study of these important patient subgroups.

5 Limitations

6 As with all observational registries there are limitations to this analysis including unmeasured or 7 residual confounders. Both race and ethnicity were defined by the subject but are social 8 constructs that may encompass a variety of genetic and cultural backgrounds. Cancelled 9 procedures are not included in the data received from the NCDR LAAO registry and hospital 10 location or region are not known. Dialysis status is unknown and adjusting for eGFR stage may 11 not capture different degrees of abnormal renal function. There is no control group, so it is 12 difficult to determine if disparities are inherent to differences in efficacy versus differences in 13 baseline risk. Only patients treated with WATCHMAN FLX are included and patients are being 14 followed for more than 2 years but this analysis is limited to 1 year follow-up. The reporting of events relies on site-reported data although algorithmic adjudication of adverse events is 15 16 employed by the NCDR LAAO registry.

17 Conclusions

This study is the largest analysis of racial and ethnic disparities in LAAO procedures in the US to date and it revealed that minorities remain significantly under-represented despite increasing procedural volumes nationally. Black patients were younger but had higher baseline comorbidities and experienced higher rates of bleeding at 45 days and 1 year and higher 1-year mortality

1 Acknowledgements

2 Funding/Support

This analysis was supported by the Boston Scientific Corporation. The authors thank and
Kristine Roy, PhD for writing/editing assistance, and Yanrong Zhu, PhD for assistance with
statistical analysis (paid employees of Boston Scientific Corporation).

6 **Disclosures**

7 The views expressed here represent those of the authors, and do not necessarily represent the

8 official views of the American College of Cardiology Foundation's National Cardiovascular

9 Data Registry (NCDR) or its associated professional societies identified at

10 CVQuality.ACC.org/NCDR. The authors interpreted the data and had final control over

11 manuscript content. The lead author (OOA) had full access to the analyzed data and attests to the

12 integrity and accuracy of the data. All authors reviewed and approved the manuscript.

13 The authors disclose the following conflicts of interest related to this manuscript. OOA:

14 Consulting, honoraria, speaking fees and proctoring fees from Boston Scientific and Edwards

15 Life Sciences; RWY: Research funding and consulting fees from Abbott Vascular, Boston

16 Scientific, and Medtronic, and research funding from Bard, Cook, and Philips; MJP: Consulting

17 honoraria, speaker's fees, and proctoring fees from Abbott Vascular and Boston Scientific,

18 consulting honoraria from W.L. Gore, Baylis Medical, Biotronik, and Philips, consulting

19 honoraria and speaker's fees from Medtronic, consulting honoraria from Biosense Webster and

20 Shockwave, and equity in Indian Wells, Inc.; JPP: Supported by R01AG074185 from the

21 National Institutes of Aging; receives grants for clinical research from Abbott, the American

22 Heart Association, the Association for the Advancement of Medical Instrumentation, Bayer,

1	Boston Scientific, iRhythm, and Philips and serves as a consultant to Abbott, Abbvie, ARCA
2	biopharma, Bayer, Boston Scientific, Bristol Myers Squibb (Myokardia), Element Science,
3	Itamar Medical, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, ReCor, Sanofi,
4	Philips, and Up-to-Date; JCH: Honoraria from Medtronic, Abbott, Boston Scientific, Biotronik,
5	Janssen Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Sanofi, Zoll Medical, iRhythm, Acutus
6	Medical, Galvanize Therapeutics, and Biosense-Webster, research grants from Biotronik and
7	Biosense-Webster, and equity interest in Vektor Medical; JVF: Research funding from the
8	NIH/NHLBI and the American College of Cardiology National Cardiovascular Data Registry
9	and consulting/advisory board fees from Medtronic, Boston Scientific, Biosense Webster,
10	PaceMate, and equity in PaceMate; BS and TC: Full-time employees and stockholders of Boston
11	Scientific. All other authors report no relationships relevant to the contents of this paper to
12	disclose.

1 **References**

- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
 Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison
 of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial
 fibrillation: a meta-analysis of randomised trials. *The Lancet*. 2014;383:955–962.
- Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P.
 Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of
 stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet*.
 2009;374:534–542.
- Essien UR, Chiswell K, Kaltenbach LA, Wang TY, Fonarow GC, Thomas KL, Turakhia
 MP, Benjamin EJ, Rodriguez F, Fang MC, Magnani JW, Yancy CW, Piccini JP Sr.
 Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in
 Patients With Atrial Fibrillation: Findings From the Get With The Guidelines–Atrial
 Fibrillation Registry. JAMA Cardiol. 2022;7:1207–1217.
- Ugowe FE, Jackson LR, Thomas KL. Racial and ethnic differences in the prevalence,
 management, and outcomes in patients with atrial fibrillation: A systematic review. *Heart Rhythm.* 2018;15:1337–1345.
- Alkhouli M, Alqahtani F, Holmes DR, Berzingi C. Racial Disparities in the Utilization and
 Outcomes of Structural Heart Disease Interventions in the United States. *J Am Heart Assoc*.
 2019;8:e012125.
- Ismayl M, Abbasi MA, Al-Abcha A, El-Am E, Walters RW, Goldsweig AM, Alkhouli M,
 Guerrero M, Anavekar NS. Racial and Ethnic Disparities in the Use and Outcomes of
 Transcatheter Mitral Valve Replacement: Analysis From the National Inpatient Sample
 Database. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2023;12:e028999.
- Reddy KP, Eberly LA, Halaby R, Julien H, Khatana SAM, Dayoub EJ, Coylewright M,
 Alkhouli M, Fiorilli PN, Kobayashi TJ, Goldberg DM, Santangeli P, Herrmann HC, Giri J,
 Groeneveld PW, Fanaroff AC, Nathan AS. Racial, Ethnic, and Socioeconomic Inequities in
 Access to Left Atrial Appendage Occlusion. *J Am Heart Assoc*. 2023;12:e028032.
- Kiernan K, Dodge SE, Kwaku KF, Jackson LR, Zeitler EP. Racial and ethnic differences in implantable cardioverter-defibrillator patient selection, management, and outcomes. *Heart Rhythm O2*. 2022;3:807–816.
- Alkhouli M, Holmes DR, Carroll JD, Li Z, Inohara T, Kosinski AS, Szerlip M, Thourani
 VH, Mack MJ, Vemulapalli S. Racial Disparities in the Utilization and Outcomes of
 TAVR: TVT Registry Report. *JACC Cardiovasc Interv*. 2019;12:936–948.
- Sparrow R, Sanjoy S, Choi Y-H, Elgendy IY, Jneid H, Villablanca PA, Holmes DR,
 Pershad A, Alraies C, Sposato LA, Mamas MA, Bagur R. Racial, ethnic and socioeconomic
 disparities in patients undergoing left atrial appendage closure. *Heart Br Card Soc.*

- 1 2021;heartjnl-2020-318650.
- Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ,
 Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR Left Atrial Appendage
 Occlusion Registry. *J Am Coll Cardiol*. 2020;75:1503–1518.
- 5 12. Centers for Medicare & Medicaid Services. Decision Memo for Percutaneous Left Atrial
 Appendage (LAA) Closure Therapy (CAG-00445N) [Internet]. 2016. Available from:
 https://www.cms.gov/medicare-coverage-database/view/ncacal-decisionmemo.aspx?proposed=N&NCAId=281
- Messenger JC, Ho KKL, Young CH, Slattery LE, Draoui JC, Curtis JP, Dehmer GJ, Grover
 FL, Mirro MJ, Reynolds MR, Rokos IC, Spertus JA, Wang TY, Winston SA, Rumsfeld JS,
 Masoudi FA. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The
 NCDR Data Quality Program in 2012. *J Am Coll Cardiol*. 2012;60:1484–1488.
- Friedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli
 S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation
 of an automated algorithm for end point adjudication for a large U.S. national registry. *Am Heart J*. 2022;254:102–111.
- Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY.
 Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure
 Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The
 PREVAIL Trial. J Am Coll Cardiol. 2014;64:1–12.
- Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant
 B, Kar S, Swarup V, Gordon N, Holmes D. Percutaneous Left Atrial Appendage Closure vs
 Warfarin for Atrial Fibrillation: A Randomized Clinical Trial. *JAMA*. 2014;312:1988.
- Vincent L, Grant J, Ebner B, Potchileev I, Maning J, Olorunfemi O, Olarte N, Colombo R,
 Marchena E de. Racial disparities in the utilization and in-hospital outcomes of
 percutaneous left atrial appendage closure among patients with atrial fibrillation. *Heart Rhythm.* 2021;18:987–994.
- Lopez J, Duarte G, Colombo RA, Ibrahim NE. Temporal Changes in Racial and Ethnic
 Disparities in the Utilization of Left Atrial Appendage Occlusion in the United States. *Am J Cardiol.* 2023;204:53–63.
- Khan MZ, Munir MB, Darden D, Pasupula DK, Balla S, Han FT, Reeves R, Hsu JC. Racial
 Disparities in In-Hospital Adverse Events Among Patients With Atrial Fibrillation
 Implanted With a Watchman Left Atrial Appendage Occlusion Device: A US National
 Perspective. *Circ Arrhythm Electrophysiol*. 2021;14:e009691.
- Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira
 L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA,
 Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With
 Atrial Fibrillation. J Am Coll Cardiol. 2022;79:1785–1798.

Holmes DR, Mack MJ, Alkhouli M, Vemulapalli S. Racial disparities and democratization
 of health care: A focus on TAVR in the United States. *Am Heart J.* 2020;224:166–170.

Tables

Table 1 Baseline Characteristics

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
	76.6 ± 7.6		75.0 ± 9.1	75.5 ± 9.0	
Age, years	(87339)	72.3 ± 9.5 (3750)	(2866)	(1082)	73.5 ± 9.1 (274)
Age group					
<70	14958 (17.1%)	1352 (36.1%)	698 (24.4%)	263 (24.3%)	85 (31.0%)
70-80	44684 (51.2%)	1658 (44.2%)	1332 (46.5%)	483 (44.6%)	129 (47.1%)
>80	27697 (31.7%)	740 (19.7%)	836 (29.2%)	336 (31.1%)	60 (21.9%)
Female	35762 (41.0%)	1834 (48.9%)	1240 (43.3%)	443 (40.9%)	120 (43.8%)
CHA ₂ DS ₂ -VASc Score	4.7 ± 1.5 (87088)	4.9 ± 1.6 (3745)	4.9 ± 1.6 (2861)	4.8 ± 1.5 (1077)	4.9 ± 1.5 (274)
Congestive heart failure	32477 (37.2%)	1835 (49.0%)	1101 (38.4%)	347 (32.1%)	116 (42.3%)
LV dysfunction	7471 (8.6%)	528 (14.1%)	310 (10.8%)	77 (7.1%)	28 (10.2%)

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
Hypertension	79721 (91.3%)	3597 (95.9%)	2689 (93.8%)	1000 (92.6%)	256 (93.4%)
Diabetes Mellitus	29429 (33.7%)	1775 (47.4%)	1462 (51.0%)	508 (47.0%)	122 (44.5%)
Stroke	17298 (19.8%)	1134 (30.3%)	760 (26.5%)	343 (31.8%)	73 (26.6%)
Transient ischemic attack	10015 (11.5%)	377 (10.1%)	297 (10.4%)	108 (10.0%)	44 (16.1%)
Thromboembolic event	12183 (14.0%)	738 (19.7%)	470 (16.4%)	183 (16.9%)	44 (16.1%)
Vascular disease	46108 (52.8%)	1808 (48.2%)	1394 (48.7%)	491 (45.5%)	148 (54.0%)
HAS-BLED Score	2.8 ± 1.1 (87081)	3.0 ± 1.2 (3742)	2.8 ± 1.2 (2861)	2.8 ± 1.1 (1077)	2.8 ± 1.2 (273)
Uncontrolled hypertension	25081 (28.7%)	1314 (35.1%)	904 (31.5%)	270 (25.0%)	70 (25.6%)
Abnormal renal function	11315 (13.0%)	1079 (28.8%)	495 (17.3%)	210 (19.4%)	51 (18.7%)
Abnormal liver function	2598 (3.0%)	136 (3.6%)	148 (5.2%)	39 (3.6%)	14 (5.1%)
Stroke	18051 (20.7%)	1162 (31.0%)	774 (27.0%)	361 (33.4%)	82 (30.0%)
Bleeding	56949 (65.3%)	2829 (75.5%)	1929 (67.3%)	745 (69.0%)	194 (71.1%)

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
Labile INR	4277 (4.9%)	173 (4.6%)	145 (5.1%)	35 (3.2%)	14 (5.1%)
Alcohol	4415 (5.1%)	145 (3.9%)	92 (3.2%)	26 (2.4%)	14 (5.1%)
Drugs – Antiplatelet	29970 (34.4%)	1325 (35.4%)	879 (30.7%)	305 (28.2%)	101 (37.0%)
Drugs – NSAIDS	11418 (13.1%)	498 (13.3%)	288 (10.1%)	106 (9.8%)	24 (8.8%)
Increased Fall Risk	36969 (42.4%)	1256 (33.6%)	1187 (41.5%)	394 (36.5%)	109 (39.9%)
Clinically relevant bleeding event	48158 (55.3%)	2712 (72.4%)	1732 (60.5%)	690 (63.8%)	162 (59.1%)
Atrial fibrillation pattern					
Paroxysmal	53806 (62.1%)	2598 (69.9%)	1782 (62.9%)	635 (59.2%)	182 (66.9%)
Persistent	18019 (20.8%)	640 (17.2%)	568 (20.0%)	217 (20.2%)	47 (17.3%)
Long-standing persistent	10189 (11.8%)	322 (8.7%)	312 (11.0%)	137 (12.8%)	30 (11.0%)
Permanent	4677 (5.4%)	159 (4.3%)	173 (6.1%)	84 (7.8%)	13 (4.8%)
Attempt at AF termination of patients	40546 (46.5%)	1325 (35.4%)	1018 (35.6%)	368 (34.0%)	102 (37.2%)

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
with AF					
Atrial flutter	15980 (18.3%)	720 (19.2%)	425 (14.9%)	163 (15.1%)	46 (16.8%)
Attempt at atrial flutter termination of	10834 (68.2%)	436 (60.8%)	282 (66.8%)	103 (63.2%)	34 (73.9%)
patients with atrial flutter					
Cardiac structural intervention	6824 (7.8%)	240 (6.4%)	218 (7.6%)	73 (6.8%)	18 (6.6%)
Hypertrophic cardiomyopathy	880 (1.0%)	70 (1.9%)	25 (0.9%)	15 (1.4%)	4 (1.5%)
Chronic lung disease	17303 (19.8%)	799 (21.3%)	415 (14.5%)	115 (10.6%)	67 (24.5%)
Coronary artery disease	38750 (44.4%)	1464 (39.1%)	1183 (41.4%)	429 (39.7%)	126 (46.0%)
Sleep apnea	26587 (30.5%)	1071 (28.6%)	667 (23.3%)	195 (18.0%)	86 (31.4%)
Sleep apnea treatment	19489 (22.5%)	727 (19.6%)	434 (15.3%)	139 (12.9%)	61 (22.3%)
	20.9 ± 4.3	22.0 ± 4.5 (3683)	20.7 ± 4.4	21.5 ± 4.3	21.2 ± 4.7 (270)
LAA orifice maximal width, mm	(85401)		(2797)	(1064)	

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
	54.3 ± 9.6	52.5 ± 12.1 (2532)	53.7 ± 10.8	55.7 ± 10.0	53.5 ± 10.6 (185)
Left ventricular ejection fraction, %	(56095)		(1801)	(668)	

Numbers are n (%) or Mean±SD (N); Abbreviations: AF=atrial fibrillation; INR=international normalized ratio; NSAIDS=Non-steroidal anti-

inflammatory drugs

Table 2 Procedural Characteristics

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
Successful implantation	85149 (97.5%)	3688 (98.4%)	2797 (97.6%)	1053 (97.3%)	264 (96.4%)
Indication for procedure [*]					

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
Increased thromboembolic stroke risk	55482 (63.6%)	2348 (62.6%)	1844 (64.3%)	723 (66.8%)	182 (66.7%)
History of major bleed	44915 (51.4%)	2562 (68.3%)	1612 (56.3%)	631 (58.3%)	151 (55.3%)
High fall risk	33484 (38.4%)	1116 (29.8%)	1081 (37.7%)	359 (33.2%)	95 (34.8%)
Labile INR	3200 (3.7%)	145 (3.9%)	109 (3.8%)	34 (3.1%)	7 (2.6%)
Patient preference	37599 (43.1%)	1322 (35.3%)	1118 (39.0%)	479 (44.3%)	117 (42.9%)
Non-compliance with anticoagulation	2806 (3.2%)	145 (3.9%)	128 (4.5%)	23 (2.1%)	12 (4.4%)
therapy					
Average number of devices used per	1.2 ± 0.5 (87339)	1.1 ± 0.4 (3750)	1.1 ± 0.4 (2866)	1.2 ± 0.4 (1082)	1.2 ± 0.55 (274)
patient					
Device size, mm					
20	10604 (12.5%)	253 (6.9%)	340 (12.2%)	79 (7.5%)	28 (10.6%)
24	26669 (31.3%)	859 (23.3%)	915 (32.7%)	279 (26.5%)	75 (28.4%)

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
27	27026 (31.7%)	1242 (33.7%)	875 (31.3%)	360 (34.2%)	85 (32.2%)
31	15163 (17.8%)	898 (24.4%)	475 (17.0%)	212 (20.1%)	54 (20.5%)
35	5687 (6.7%)	436 (11.8%)	192 (6.9%)	123 (11.7%)	22 (8.3%)
	78.0 ± 66.2	84.9 ± 57.5 (3750)	88.9 ± 274.1	84.7 ± 86.6	75.2 ± 37.2 (274)
Procedure time, minutes	(87336)		(2866)	(1081)	
	37.9 ± 33.2	36.5 ± 33.9 (3558)	43.6 ± 37.1	38.9 ± 34.8	40.6 ± 31.2 (267)
Contrast volume, mL	(84440)		(2736)	(1039)	
General anesthesia	82633 (94.8%)	3544 (94.8%)	2736 (95.8%)	1033 (95.8%)	265 (96.7%)
Concomitant procedure performed	1776 (2.0%)	86 (2.3%)	59 (2.1%)	18 (1.7%)	8 (2.9%)
	2.0 ± 6.76	2.6 ± 9.05 (3750)	2.6 ± 10.19	2.2 ± 2.75	1.8 ± 1.19 (274)
Length of stay, days	(87339)		(2866)	(1082)	
Same day discharge	30301 (34.7%)	940 (25.1%)	652 (22.8%)	287 (26.5%)	114 (41.6%)

					American Indian/
			Hispanic/		Alaska Native or
		Black/African	Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
Residual leak post procedure					
0 mm	81155 (96.4%)	3466 (94.8%)	2661 (96.7%)	980 (94.6%)	242 (94.5%)
$>0 \text{ mm to } \leq 3 \text{ mm}$	2414 (2.9%)	165 (4.5%)	77 (2.8%)	43 (4.2%)	11 (4.3%)
>3 mm to ≤5 mm	571 (0.7%)	24 (0.7%)	13 (0.5%)	11 (1.1%)	3 (1.2%)
>5 mm	19 (0%)	1 (0.03%)	0 (0%)	2 (0.2%)	0 (0%)
Patients with missing leak data	3180	94	115	46	18

Numbers are n (%) or Mean±SD (N); *patients can have more than one indication; Abbreviations: INR=international normalized ratio

Table 3 Discharge Medication Regimens

Table 5 Discharge Medica					American Indian/ Alaska Native or
		Black/African	Hispanic/ Latinx		Native Hawaiian/
	White	American	Ethnicity	Asian	Pacific Islander
Description	(N = 87339)	(N = 3750)	(N = 2866)	(N = 1082)	(N = 274)
DOAC alone	13623 (22.7%)	604 (23.0%)	581 (30.7%)	206 (20.2%)	39 (20.4%)
DOAC + ASA	29245 (48.7%)	1248 (47.5%)	785 (41.5%)	317 (43.4%)	98 (51.3%)
DOAC + P2Y12 inhibitor	3005 (5.0%)	90 (3.4%)	103 (5.5%)	41 (5.6%)	9 (4.7%)
Warfarin alone	1496 (2.5%)	58 (2.2%)	41 (2.2%)	13 (1.8%)	11 (5.8%)
Warfarin + ASA	4521 (7.5%)	148 (5.6%)	92 (4.9%)	37 (5.1%)	11 (5.8%)
Warfarin + P2Y12 inhibitor	408 (0.68%)	11 (0.42%)	14 (0.74%)	6 (0.82%)	3 (1.6%)
DAPT	4805 (8.0%)	296 (11.3%)	132 (7.0%)	66 (9.0%)	11 (5.8%)
SAPT	1482 (2.5%)	110 (4.2%)	65 (3.4%)	25 (3.4%)	2 (1.1%)
Triple Therapy	1.5% (1.5%)	37 (1.4%)	34 (1.8%)	14 (1.9%)	3 (1.6%)
Other	233 (0.39%)	10 (0.38%)	19 (1.0%)	3 (0.41%)	0 (0.0%)
No OAC or APT	403 (0.67%)	16 (0.61%)	24 (1.3%)	2 (0.27%)	4 (2.1%)

Numbers are n (%) or Mean±SD (N); Other=[Warfarin + DOAC + P2Y12 inhibitor] or [Warfarin + DOAC + ASA] or [Warfarin + DOAC

Abbreviations: APT=antiplatelet therapy, DAPT=dual antiplatelet therapy, DOAC=direct oral anticoagulant, OAC=oral anticoagulant, SAPT=single antiplatelet therapy

	Black/African American		Hispanic/Latinx Ethnicity		
	Univariate	Multivariate	Univariate	Multivariate	
	HR [95% CI]	HR [95% CI]	HR [95% CI]	HR [95% CI]	
45 days					
All Death	1.39 [1.00, 1.94]	1.18 [0.83, 1.67]	1.11 [0.72, 1.70]	1.15 [0.75, 1.77]	
All Stroke	1.30 [0.74, 2.28]	1.15 [0.65, 2.02]	1.10 [0.54, 2.23]	1.04 [0.51, 2.12]	
Ischemic Stroke	1.69 [0.96, 2.98]	1.50 [0.85, 2.64]	1.07 [0.48, 2.43]	1.06 [0.47, 2.40]	
Major Bleeding*	1.64 [1.39, 1.92]	1.30 [1.10, 1.54]	0.99 [0.79, 1.25]	0.90 [0.71, 1.15]	
1 year					
All Death	1.37 [1.17, 1.61]	1.26 [1.06, 1.50]	1.04 [0.83, 1.29]	0.99 [0.79, 1.25]	
All Stroke	1.38 [0.97, 1.96]	1.12 [0.77, 1.63]	1.06 [0.65, 1.73]	1.09 [0.67, 1.79]	
Ischemic Stroke	1.57 [1.08, 2.28]	1.24 [0.83, 1.85]	1.12 [0.66, 1.92]	1.13 [0.66, 1.94]	
Major Bleeding*	1.75 [1.50, 2.04]	1.36 [1.15, 1.60]	0.99 [0.78, 1.25]	0.89 [0.69, 1.14]	

Table 4. Outcomes in the adjusted cohorts through 45 day and 1 year follow-up visits

Hazard ratio (HR) [95% confidence interval]; reference White patients; *any bleeding requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. Multivariable models adjusted for age, gender, CHA₂DS₂-VASc and HAS-BLED score components, type of atrial fibrillation, diabetes, fall risk, history of bleeding, chronic lung disease, sleep apnea, cardiomyopathy, coronary artery disease, prior ablation, left ventricular ejection fraction and post implant device margin residual leak.






Figure 1. Outcomes at 45 day and 1 year by race and ethnicity Time-to-event outcomes at (A) 45 days and (B) 1 year by race and ethnicity in patients implanted

with WATCHMAN FLX.




Figure 2. Unadjusted and Adjusted Outcomes of Adverse Events for White, Black/African


American, and Hispanic/Latinx Patients Receiving WATCHMAN FLX

P-value from the log-rank test. Hazard ratio (HR) [95% confidence interval]; reference White patients;

*Major bleeding defined as bleeding requiring hospitalization, and/or causing a decrease in hemoglobin

|evel > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. Multivariable models adjusted for age, gender, CHA_2DS_2 -VASc and HAS-BLED score components, type of atrial fibrillation, diabetes, fall risk, history of bleeding, chronic lung disease, sleep apnea, cardiomyopathy, coronary artery disease, prior ablation, left ventricular ejection fraction and post implant device margin residual leak.

Racial and Ethnic Disparities in the Utilization and Outcomes with WATCHMAN FLX: A SURPASS analysis of the NCDR LAAO Registry



Graphic Abstract

What is known:

There is underutilization of LAAO among racial and ethnic minority patients with AF and there are racial and ethnic differences in periprocedural outcomes.

What this study adds:

In this study from a large US national registry of patients undergoing LAAO, Black patients were younger but had higher baseline comorbidities and experienced higher rates of bleeding at 45 days and 1-year and higher 1-year mortality. Further work is needed to enroll diverse patients into research trials and to provide equitable AF-related access to advanced care and intra-procedural and post-procedural care in US real-world practice.